Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBarbui, Tiziano
dc.contributor.authorIurlo, Alessandra
dc.contributor.authorMasciulli, Arianna
dc.contributor.authorCarobbio, Alessandra
dc.contributor.authorGhirardi, Arianna
dc.contributor.authorRossi, Giuseppe
dc.contributor.authorFox, Maria Laura
dc.date.accessioned2022-04-06T07:03:34Z
dc.date.available2022-04-06T07:03:34Z
dc.date.issued2021-06-16
dc.identifier.citationBarbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, et al. Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 Jun 16;11:115.
dc.identifier.issn2044-5385
dc.identifier.urihttps://hdl.handle.net/11351/7308
dc.descriptionCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Neoplàsies mieloproliferatives cròniques
dc.description.sponsorshipThe study was supported by a research grant by the COVID “3×1 project”, BREMBO S.p.A., Bergamo, Italy (TB) and by AIRC 5×1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (AMV, PG). The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofseriesBlood Cancer Journal;11
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia) - Tractament
dc.subjectTrastorns mieloproliferatius - Complicacions
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshMyeloproliferative Disorders
dc.subject.mesh/complications
dc.subject.meshCoronavirus Infections
dc.subject.mesh/therapy
dc.titleLong-term follow-up of recovered MPN patients with COVID-19
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41408-021-00509-0
dc.subject.decstrastornos mieloproliferativos
dc.subject.decs/complicaciones
dc.subject.decsinfecciones por Coronavirus
dc.subject.decs/terapia
dc.relation.publishversionhttps://doi.org/10.1038/s41408-021-00509-0
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Barbui T, Masciulli A, Carobbio A, Ghirardi A] FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. [Iurlo A] Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. [Rossi G] Spedali Civili, Brescia, Italy. [Fox ML] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34135309
dc.identifier.wos000664631700002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple